Quest Diagnostics Incorporated (DGX) News
Quest Diagnostics Incorporated (DGX)
Today's Latest Price: $115.35 USD
Updated Jul 2 11:13am
Add DGX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
Filter DGX News Items
DGX News Results
| Event/Time | Symbol | Company | News Detail | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest DGX News From Around the Web
Below are the latest news stories about Quest Diagnostics Inc that investors may wish to consider to help them evaluate DGX as an investment opportunity.
Quest, LabCorp warn of coronavirus testing delays as demand surges amid outbreaksQuest Diagnostics and LabCorp said there will be delays in coronavirus testing results as demand surges with outbreaks. |
Masimo's New Solution to Reduce Opioid Withdrawal SymptomsMasimo's (MASI) new solution can help reduce symptoms associated with opioid withdrawal, thereby helping OUD patients with their treatment. |
Bio-Rad Rides on PCR Test Kits for Coronavirus Amid Cost WoeThe uptick in Bio-Rad's (BIO) core PCR and Droplet Digital PCR product revenues is the result of robust demand due to coronavirus testing and related research. |
Insurer Humana teams up with Walmart, Quest, LabCorp for COVID-19 testingU.S. health insurer Humana Inc will offer its members at-home COVID-19 test collection kits, as well as provide access to drive-through testings at the hundreds of neighborhood markets of Walmart Inc, it said on Tuesday. For drive-through testing, the insurer said it has tied up with the retail chain and Quest Diagnostics. Humana said new testing sites at Walmart pharmacies will be added between now and August for pharmacist-observed testing. |
Luminex Expands COVID-19 Testing With New Antibody TestLuminex (LMNX) submits an EUA request to the FDA for its first multi-antigen IgG assay. |
Quest Diagnostics Marks 10 Years of Commitment to Reducing Employee Cancer Risk as CEO Cancer Gold Standard™ EmployerQuest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, marks its 10-year anniversary as a CEO Cancer Gold Standard™ employer this year, signifying its commitment to implementing employee health strategies that will reduce cancer risk among its workforce. |
Myriad Genetics' myPath Melanoma Proved Superior Per New StudyMyriad Genetics' (MYGN) myPath Melanoma's accuracy to classify skin lesions, termed as indeterminate by standard pathological review, validated by the latest study. |
Here's Why You Should Hold on to Illumina Stock for NowInvestors continue to be optimistic about Illumina (ILMN) backed by its focus on partnerships and robust demand for its products. |
CEO Roundtable on Cancer Celebrates Employers marking Ten-Year CEO Cancer Gold Standard™ AnniversaryThe CEO Cancer Gold Standard™, the employer-led health and wellness accreditation program of the CEO Roundtable on Cancer, is now helping more than seven million employees and their family members prevent and address cancer through workplace-based programming. This year, 18 Gold Standard employers mark their ten-year anniversary as Gold Standard employers, having maintained a strong commitment to the health of their employees and satisfying the latest, comprehensive requirements of the Gold Standard. |
Ooma, Chico's, Ericsson, Quest and Kroger as Zacks Bull and Bear of the DayOoma, Chico???s, Ericsson, Quest and Kroger as Zacks Bull and Bear of the Day |
